CDD for Apposite Capital’s acquisition of 1MED

Apposite Capital, a healthcare specialist private equity investor, has acquired 1MED, a fast-growing Contract Research Organisation (“CRO”) for clinical and regulatory support, specialising in the medical device sector.

1MED is a specialist CRO that supports the commercialisation of new medical technologies and products by providing regulatory strategy, clinical trial management and quality assurance services across a broad range of therapeutic areas and product types. It is recognised as a high quality and reliable outsourced provider to obtain product certification on time and budget with a 100% product approval rate to date.

The company was founded in 2014 and is headquartered in Agno, Switzerland. 1MED operates in a fast-growing market where over 40% of clinical development is currently outsourced, as medical device and pharmaceutical companies seek to reduce their R&D expenditure and face an increasingly more complex regulatory environment. The new MDR and IVDR regulatory frameworks coming into effect in 2021 and 2022 will increase the need to work with specialist outsourcing firms such as 1MED. The company’s client base consists primarily of European medical device and pharma companies.

PMSI provided CDD on the deal, including analysis of the competitive landscape, market sizing, and customer referencing, as well as deeper analysis and forecasting of the effects of upcoming changes to European MDR and IVDR regulatory frameworks on the company’s customer base and the subsequent addressable market size.

Anne-Laure Meynier, Apposite Capital:

“PMSI were instrumental in confirming the high quality of 1Med’s services and the continuous trust from existing customers and allowed us to move quickly in improving our understanding of the development and growth potential of the existing pipeline and expansion of the existing customer relationships.”